Larvol Delta - Cerecor-Announces-CERC002-Signicantly-Reduced-Respiratory-Failure-and-Mortality-in-Phase-2-Clinical-Trial-in-Patients-Hospitalized-with-COVID19-ARDS

CERC-002 - Kyowa Hakko Kirin, Sanofi, Cerecor

http://www.globenewswire.com/news-release/2021/03/02/2185086/0/en/Cerecor-Announces-CERC-002-Significantly-Reduced-Respiratory-Failure-and-Mortality-in-Phase-2-Clinical-Trial-in-Patients-Hospitalized-with-COVID-19-ARDS.html

Mar 2, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next